Ibrutinib for Chronic Lymphocytic Leukemia
Authors:
- Jan A BurgerJBJan A Burger
- Lori StylesLSLori Styles
- Thomas J KippsTKThomas J Kipps
- 21 April 2016
- journal article
- letter
- Published by Massachusetts Medical Society in New England Journal of Medicine
- Vol. 374 (16) , 1592-1595
Abstract
To the Editor: It is not surprising that Burger et al. (Dec. 17 issue)1 report positive results in the Study of Ibrutinib as Initial Therapy for Patients with Chronic Lymphocytic Leukemia (RESONATE-2), a randomized trial of ibrutinib versus chlorambucil in older patients with chronic lymphocytic leukemia (CLL). Chlorambucil has served as a comparator in trials of bendamustine, alemtuzumab, ofatumumab, and obinutuzumab, and longer durations of progression-free survival have been reported with each agent.25 In addition, these trials have shown longer durations of overall survival with the use of ibrutinib and obinutuzumab.1,2We reviewed our experience in the Connect . . .Keywords
This publication has 9 references indexed in Scilit:
- Ibrutinib as Initial Therapy for Patients with Chronic Lymphocytic LeukemiaNew England Journal of Medicine, 2015
- Chlorambucil plus ofatumumab versus chlorambucil alone in previously untreated patients with chronic lymphocytic leukaemia (COMPLEMENT 1): a randomised, multicentre, open-label phase 3 trialThe Lancet, 2015
- Outcomes of patients with chronic lymphocytic leukemia after discontinuing ibrutinibBlood, 2015
- Ibrutinib for previously untreated and relapsed or refractory chronic lymphocytic leukaemia with TP53 aberrations: a phase 2, single-arm trialThe Lancet Oncology, 2015
- Obinutuzumab plus Chlorambucil in Patients with CLL and Coexisting ConditionsNew England Journal of Medicine, 2014
- Impact of Age on Outcomes After Initial Therapy With Chemotherapy and Different Chemoimmunotherapy Regimens in Patients With Chronic Lymphocytic Leukemia: Results of Sequential Cancer and Leukemia Group B StudiesJournal of Clinical Oncology, 2013
- First-line therapy with fludarabine compared with chlorambucil does not result in a major benefit for elderly patients with advanced chronic lymphocytic leukemiaBlood, 2009
- Phase III Randomized Study of Bendamustine Compared With Chlorambucil in Previously Untreated Patients With Chronic Lymphocytic LeukemiaJournal of Clinical Oncology, 2009
- Alemtuzumab Compared With Chlorambucil As First-Line Therapy for Chronic Lymphocytic LeukemiaJournal of Clinical Oncology, 2007